ATR-107 is a humanized monoclonal antibody inhibitor targeting interleukin-21 receptor (IL-21R). It holds potential for research in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.
Target:
Interleukin
* VAT and and shipping costs not included. Errors and price changes excepted
